SISRAM MED (01696) announced its annual results for the year ended December 31, 2025. The group recorded revenue of $365 million, representing a 4.7% increase compared to the previous year. Profit attributable to owners of the parent company was $19.016 million, down 24.32% year-on-year. Basic earnings per share stood at 4.06 U.S. cents. The company proposed a final dividend of HK$0.095 per share.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.